Abstract
Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95% confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47%, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.
| Original language | English |
|---|---|
| Pages (from-to) | 403-410 |
| Number of pages | 8 |
| Journal | Journal of Alzheimer's Disease |
| Volume | 48 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 09-09-2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health
Cite this
}
Lithium as a Treatment for Alzheimer's Disease : A Systematic Review and Meta-Analysis. / Matsunaga, Shinji; Kishi, Taro; Annas, Peter; Basun, Hans; Hampel, Harald; Iwata, Nakao.
In: Journal of Alzheimer's Disease, Vol. 48, No. 2, 09.09.2015, p. 403-410.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Lithium as a Treatment for Alzheimer's Disease
T2 - A Systematic Review and Meta-Analysis
AU - Matsunaga, Shinji
AU - Kishi, Taro
AU - Annas, Peter
AU - Basun, Hans
AU - Hampel, Harald
AU - Iwata, Nakao
PY - 2015/9/9
Y1 - 2015/9/9
N2 - Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95% confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47%, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.
AB - Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95% confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47%, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.
UR - http://www.scopus.com/inward/record.url?scp=84941278298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941278298&partnerID=8YFLogxK
U2 - 10.3233/JAD-150437
DO - 10.3233/JAD-150437
M3 - Review article
C2 - 26402004
AN - SCOPUS:84941278298
VL - 48
SP - 403
EP - 410
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - 2
ER -